Abstract: The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
Type:
Application
Filed:
May 1, 2023
Publication date:
April 25, 2024
Inventors:
David C. Myles, Peter J. Kushner, Cyrus L. Harmon
Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
Abstract: Pharmaceutical compositions suitable for oral administration (such as a tablet or a capsule) are provided, which comprise a therapeutically effective amount of an amorphous solid dispersion of cabozantinib, e.g., for treating a proliferative disorder. Preferably, the amorphous solid dispersion consists of (a) cabozantinib or a pharmaceutically acceptable salt thereof (such as cabozantinib (S)-malate); (b) at least one pharmaceutically acceptable carrier selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine and vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), and mixtures thereof; (c) a pore-forming agent; and (d) a plasticizer.
Type:
Application
Filed:
November 29, 2023
Publication date:
April 25, 2024
Applicant:
SLAYBACK PHARMA LLC
Inventors:
Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
Abstract: Methods and composition for treating or preventing a lung infection, or related symptoms, caused by a bacterium, fungus, and/or virus using an effective amount of tafenoquine are disclosed. Methods and compositions for treating or preventing a lung infection in a human that is infected with SARS-CoV-2 using tafenoquine are disclosed.
Abstract: The present invention provides formulations of (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone, and methods of making and using the same.
Type:
Application
Filed:
October 5, 2023
Publication date:
April 25, 2024
Inventors:
Rick Bastin, Alaa Hosny, Dolly Jacob, Wu Lin
Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
Type:
Application
Filed:
November 1, 2023
Publication date:
April 25, 2024
Inventors:
Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
Abstract: The subject invention pertains to compositions comprising an opioid receptor antagonist and an opioid receptor agonist and methods of inhibiting an opioid overdose in a subject. The opioid receptor antagonist can be naloxone or a derivative thereof, while the opioid receptor agonist can be nalbuphine or a derivative thereof. The composition can be administered intranasally, intravenously and by autoinjector. The reversal time can be about three minutes.
Type:
Application
Filed:
June 14, 2023
Publication date:
April 25, 2024
Inventors:
John ABERNETHY, Georgiy NIKONOV, Michael VORONKOV
Abstract: This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.
Type:
Application
Filed:
September 1, 2023
Publication date:
April 25, 2024
Inventors:
LAWRENCE B. Snyder, Andrew P. Crew, Jing Wang, Hanqing Dong
Abstract: The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
Type:
Application
Filed:
October 31, 2023
Publication date:
April 25, 2024
Inventors:
Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver
Abstract: This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.
Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.
Type:
Application
Filed:
April 26, 2023
Publication date:
April 25, 2024
Inventors:
Anthony H. Cincotta, Craig Michael Bowe, Paul Clark Stearns, Laura Jean Weston
Abstract: The present invention relates to a pharmaceutical composition comprising a novel compound as an active ingredient for prevention or treatment of transplant rejection. The novel compound SD911 of the present invention was identified to repress the migration of immune cells, increase the engraftment and viability of a grafted tissue, and regulate immune cells. In addition, it was found in a kidney transplantation model that the compound restrained human PBMC from suppressing the engraftment and damaging renal tissues and downregulated the expression of the inflammatory cytokine IL-17, with the consequent effective prevention and treatment of transplant rejection.
Type:
Application
Filed:
April 6, 2022
Publication date:
April 25, 2024
Applicant:
THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors:
Chul Woo YANG, Dongyun SHIN, Sun Woo LIM, Mi La CHO, Yoo Jin SHIN, Seon Yeong LEE, A Ram LEE
Abstract: The present invention relates to a method of chemovaccination against Plasmodium infection comprising administering to a patient an effective amount of a selective inhibitor of plasmepsin X, or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
February 2, 2022
Publication date:
April 25, 2024
Applicants:
Merck Sharp & Dohme LLC, The Walter and Eliza Hall Institute of Medical Research
Inventors:
Justin A. Boddey, David B. Olsen, Ryan Steel, John A. McCauley, Manuel De Lera Ruiz
Abstract: Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.
Abstract: Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine to a human being in need thereof. Reboxetine may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
Abstract: Disclosed herein are methods, pharmaceutical compositions, and vaccines for modulating an immune response. Also disclosed herein are methods, pharmaceutical compositions, and vaccines for inducing an immune response.
Type:
Application
Filed:
October 15, 2020
Publication date:
April 25, 2024
Inventors:
Benjamin CRAVATT, Ekaterina VINOGRADOVA, Vincent CROWLEY, Xiaoyu ZHANG, Michael Andreas SCHAFROTH, Minoru YOKOYAMA, Dave REMILLARD, Bruno MELILLO, Stuart SCHREIBER
Abstract: This invention relates to a method of treating damage to the central nervous system, comprising administering a pharmaceutically-effective amount of a CCR5 antagonist, and a pharmaceutically effective amount of an AQP4 antagonist, or pharmaceutically acceptable salts thereof.
Type:
Application
Filed:
February 4, 2022
Publication date:
April 25, 2024
Inventors:
Roslyn Mary Bill, Stuart David Greenhill, Luke David Southan
Abstract: The present invention provides methods of treating a S. aureus bloodstream infection (bacteremia) to a patient in need thereof, the method comprising administering ceftobiprole as ceftobiprole miedocaril to the patient at a dosage corresponding to 500 mg of ceffobiprole every 6 hours on days 1 to 8 and 500 mg every 8 hours on days 9 onwards.
Abstract: The present disclosure provides for pharmaceutical composition and methods of treating a condition using the pharmaceutical composition. The condition to be treated in a subject in need of treatment can include an infection or non-viral hyper-inflammation/immune hyperactivation condition. The infection can be a coronavirus infection, HIV infection, influenza infection, or the like, where a direct or indirect result of the infection can be respiratory distress, oxidative stress, and the like that can lead to acute respiratory distress syndrome (ARDS) and/or organ dysfunction or failure.
Type:
Application
Filed:
July 1, 2021
Publication date:
April 25, 2024
Inventors:
Andrzej T. SLOMINSKI, Chander RAMAN, Shariq QUAYYUM
Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans streptococci, Enterococcus, or combinations thereof.
Type:
Application
Filed:
August 27, 2023
Publication date:
April 25, 2024
Inventors:
Sean M. Johnston, Robert D. Arbeit, Thomas J. Bigger, Dennis P. Molnar, S. Ken Tanaka
Abstract: The present disclosure relates generally to pharmaceutical compositions comprising cannabidiol (CBD), ?-9-tetrahydrocannabinol (THC) and linalool. In some embodiments, the pharmaceutical compositions are useful in the treatment of an inflammatory condition, e.g., useful for the treatment of pain.
Type:
Application
Filed:
December 6, 2021
Publication date:
April 25, 2024
Applicant:
Cymra Life Sciences Limited
Inventors:
Joel Ernest George Hardy, Simon Kenneth Pettinger, John Montgomery, Matthew Turner
Abstract: The invention relates to compositions and formulations for the treatment of disorders of the gastrointestinal (GI) tract. Also provided are methods for treating, preventing, and/or alleviating disorders of the GI tract.
Abstract: Various aspects of this disclosure relate to a composition, comprising a liquid phase that comprises a plurality of cations, an anion, a molecule, a base, and a solvent, wherein the plurality of cations, the anion, the molecule, and the base are solutes that are dissolved in the solvent; each cation of the plurality of cations is a metal cation or an ammonium cation; the molecule is a cannabinoid; the solvent is not water; the solvent has a solubility in water at 37 degrees Celsius of at least 25 grams per liter; each cation of the plurality of cations has a net charge of 1, 2, or 3; the anion has a net charge of ?1; the molecule lacks a net charge; the base has a net charge of ?1; the composition has a molar concentration for the anion, the molecule, the base, and each cation of the plurality of cations; the composition has an equivalent concentration for each cation of the plurality of cations, which is equal to the molar concentration of a cation multiplied by the net charge of the same cation; the composi
Abstract: The present invention relates to the use of cannabidivarin (CBDV) for the treatment of seizures associated with canine epilepsy. In a further embodiment the CBDV used is in the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 1.5% (w/w).
Abstract: A method of reducing symptoms of a neurodegenerative disease comprising administering an effective amount of cannabidiol to a subject in need thereof to improved cognitive function and ameliorated the pathophysiology of the neurodegenerative disease.
Type:
Application
Filed:
February 16, 2022
Publication date:
April 25, 2024
Applicant:
AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
Inventors:
Babak BABAN, Jack YU, Krishnan M. DHANDAPANI
Abstract: The present disclosure relates to the use of certain steroids for the diagnosis and treatment of necrotizing enterocolitis and pre-eclampsia.
Abstract: There is provided with a method for treating cancer, comprising administering a pharmaceutical composition to a patient with cancer in combination with an anti-cancer agent, the pharmaceutical composition. A compound is represented by General Formula (I) or a pharmaceutically acceptable salt thereof: where R1 is an acyl residue from a fatty acid.
Type:
Application
Filed:
October 10, 2023
Publication date:
April 25, 2024
Applicants:
M.T.3, Inc., Colorado State University Research Foundation
Abstract: [Problem] The present invention has as an object to provide an antiviral agent effective as a remedy for COVID-1 9 and other viral infections. [Resolution Means] Provided is an antiviral agent and the like, made of: the compound represented by general formula (1) or (2) below [R1 being —(CH2)n1—Z1—R11 2 r —CH—(—Z1—R11,)(n1 being 0 or 1; Z1 being a single bond, —O—, —NH—, —S—, —SO—, —SO2—,SO—CO—, —CO—O—, or —CH?N—O—; R11 being a hydrogen atom, an alkyl group having 1 to 6 carbons, —NR12 R13, —N3,—NO2,—CN, —CH2—CO—O—R14, or a five- or six-membered heterocyclic group including a nitrogen atom; R12 and R13 each independently being a hydrogen atom or an alkyl group having 1 to 6 carbons; and R14 being a hydrogen atom or an alkyl group having 1 to 6 carbons], a derivative thereof, a salt of these compounds, or a solvate thereof.
Abstract: In one aspect disclosed herein are small molecule inhibitors of CD38 and their use in treating, inhibiting, decreasing, reducing, ameliorating and/or preventing graft versus host disease, ischemia reperfusion injury, graft rejection, inflammatory injury to a graft or a graft recipient. Additionally, disclosed herein are methods of inhibiting CD38 pathway and activity comprising contacting a cell expressing CD38 or administering to a subject in need of CD38 inhibition, any of the small molecule CD38 inhibitors disclosed herein.
Type:
Application
Filed:
February 8, 2022
Publication date:
April 25, 2024
Inventors:
Sylvester Michael BLACK, Bryan Alan WHITSON, Blake Robert PETERSON, Austin SCHENK
Abstract: The present disclosure includes cationic carrier units comprising (i) a water-soluble polymer, (ii) a positively charged carrier, (iii) a hydrophobic moiety, and (iv) a crosslinking moiety, wherein when the cationic carrier unit is mixed with an anionic payload (e.g., an antisense oligonucleotide) that electrostatically interacts with the cationic carrier unit, the resulting composition self-organizes into a micelle encapsulating the anionic payload in its core. The cationic carrier units can also comprise a tissue specific targeting moiety, which would be displayed on the surface of the micelle. The disclosure also includes micelles comprising the cationic carrier units of the disclosure, methods of manufacture of cationic carrier units and micelles, pharmaceutical compositions comprising the micelles, and also methods of treating diseases or conditions comprising administering the micelles to a subject in need thereof.
Type:
Application
Filed:
December 29, 2021
Publication date:
April 25, 2024
Applicant:
BIORCHESTRA CO., LTD.
Inventors:
Jin-Hyeob RYU, Yu Na LIM, Hyun Su MIN, Han Seok KOH, Dae Hoon KIM, Hyun-Jeong CHO
Abstract: Disclosed herein are circular RNAs and transfer vehicles, along with related compositions and methods of treatment. The circular RNAs can comprise group I intron fragments, spacers, an IRES, duplex forming regions, and/or an expression sequence, thereby having the features of improved expression, functional stability, low immunogenicity, ease of manufacturing, and/or extended half-life compared to linear RNA. Pharmaceutical compositions comprising such circular RNAs and transfer vehicles are particularly suitable for efficient protein expression in immune cells in vivo. Also disclosed are precursor RNAs and materials useful in producing the precursor or circular RNAs, which have improved circularization efficiency and/or are compatible with effective circular RNA purification methods.
Type:
Application
Filed:
May 18, 2023
Publication date:
April 25, 2024
Inventors:
Brian Goodman, Robert Alexander Wesselhoeft, Allen T. Horhota, Junghoon Yang
Abstract: This current invention provides methods and agents for preventing and treating autoimmune and lymphoproliferative disease by targeting pathogenic age-associated B cells as well as methods of detecting these pathogenic age-associated B cells as a method of diagnosing and predicting autoimmune disease and other lymphoproliferative and chronic inflammatory disorders. The current invention also provides targets for drug development and basic research for autoimmune diseases and other lymphoproliferative and chronic inflammatory disorders.
Abstract: The present invention includes methods of treatment and/or prevention of fibrosis and of diseases associated with fibrosis by administering an, agent being selected from among: a combination of: miR-34b or a precursor or a mimic or a functional derivative thereof and miR-34c or a precursor or a mimic or a functional derivative thereof; or miR-34b or a precursor or a mimic or a functional derivative thereof or miR-34c or a precursor or a mimic or a functional derivative thereof.
Type:
Application
Filed:
February 28, 2022
Publication date:
April 25, 2024
Applicant:
FONDAZIONE TELETHON ETS
Inventors:
Nicola BRUNETTI PIERRI, Pasquale PICCOLO, Rosa FERRIERO
Abstract: The present invention relates to a carboxyalkyl chitosan having a zeta potential, measured at pH 7.5, that is less than or equal to ?20 mV, compositions comprising same, a process for manufacturing same, and various applications thereof, in particular in the field of therapy, rheumatology, ophthalmology, esthetic medicine, plastic surgery, internal surgery, dermatology or cosmetics.
Type:
Application
Filed:
December 21, 2023
Publication date:
April 25, 2024
Inventors:
Mickaël Chausson, Pierre Douette, Sandrine Emilia Gautier, Philippe Vaesen, Houtaï Choumane, Guillermo Rocasalbas
Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for delivery of agents to biological surfaces and/or the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compositions for treating disorders including diabetes type II and clinical obesity that require a modulation of certain nutrients to the body.
Type:
Application
Filed:
April 26, 2023
Publication date:
April 25, 2024
Inventors:
Jeffrey M. Karp, Yuhan Lee, Ali Tavakkoli, Tarawatie E. Deelman
Abstract: A dosing regimen for administering a composition to a patient for treatment of congestion or irritation includes administering a first dose of the composition to the patient. The composition is formulated as an aqueous solution including between about 0.125 to about 1 milliequivalents of sodium bicarbonate per milliliter of the aqueous solution. The first dose includes between about 0.25 to about 1 milliliter of the composition. The dosing regimen also includes administering a second dose of the composition to the patient after administration of the first dose. The second dose includes between about 0.25 to about 1 milliliter of the composition.
Abstract: Disclosed herein are methods for otoprotection against platinum-based antineoplastic agents by administering a thiosulfate salt to a subject in need thereof. Typically, the thiosulfate salt is administered to the subject scheduled to be administered a platinum-based antineoplastic agent within 4 hours. Alternatively, the thiosulfate salt is administered within 7 hours after the administration of a platinum-based neoplastic agent.
Type:
Application
Filed:
May 22, 2023
Publication date:
April 25, 2024
Inventors:
John LEE, John R. SOGLIA, Qi-Ying HU, Fuxin SHI
Abstract: The present disclosure is directed to ready-to-use, injectable formulations of a liquid pharmaceutical composition comprising sodium bicarbonate, and methods of treatment using said formulations.
Abstract: The present invention relates to a composition for treating inflammatory diseases comprising germanium telluride nanosheets coated with polyvinylpyrrolidone, and the nanosheets have excellent anti-inflammatory and thus are excellent in treating inflammatory bowel disease and psoriasis.
Type:
Application
Filed:
December 28, 2023
Publication date:
April 25, 2024
Inventors:
Kyung-Hwa Yoo, Jun Ho Song, Yong-Beom Park, Sun-Mi Lee, Chin Hee Min, Taejun Yoon
Abstract: A medical device for repairing a lesion in a spinal cord or in a peripheral nerve is provided. The medical device has a flexible support made of expanded polytetrafluoroethylene. Stem cells suitable for being oriented along a first growth direction or a second growth direction are at least partially embedded on the flexible support that is suitable for taking an extended configuration and a wound configuration. In the wound configuration, the flexible support is suitable for being wound around the spinal cord so that the first and second growth directions are substantially statistically parallel to a neuronal extension direction of neurons of the spinal cord. Surgical methods of treating a spinal injury involving using the medical device are also provided.
Abstract: The invention relates to compounds based on a recombinant form of the CCP6 region of C4BP and an oligomerization domain for use in the prevention and/or treatment of immunological diseases. Moreover, the invention relates to methods for obtaining tolerogenic dendritic cells and tolerogenic macrophages using the compounds of the invention and to the cells obtained by these methods and their therapeutic uses.
Type:
Application
Filed:
October 18, 2020
Publication date:
April 25, 2024
Inventors:
Josep M. ARAN PERRAMON, Ana LUQUE GÒMEZ, Inmaculada SERRANO SANTACRUZ
Abstract: The invention relates to a dendritic cell (DC) vaccine for use in a method of treating cancer in a patient, wherein the patient is selected for treatment with said DC vaccine. The selection inter alia comprises determining in a tumor sample from the patient the amount of CD8+ T-cells and/or the tumor mutation burden (TMB) and comparing the determined amount to a predetermined threshold level. The selection allows identifying patients that particularly benefit from DC treatment.